Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Wyeth, Progenics Drug Clears EC | Contract Pharma

What are you searching for?

Sign in

Wyeth, Progenics Drug Clears EC

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Relistor subcutaneous injection, a treatment for opioid-induced constipation (OIC), has been approved by the European Commission. The drug, developed by Wyeth and Progenics, is now approved in the 27 member states of the European Union as well as Iceland, Norway, and Liechtenstein. Relistor is the first approved treatment for OIC in the European Union.

“The approval of Relistor by the European Commission is another major milestone for this innovative therapy, the first medicine approved for the treatment of opioid-induced constipation in advanced illness patients,” said Paul J. Maddon, M.D., Ph.D., founder, chief executive officer and chief science officer of Progenics.

Joseph M. Mahady, president, Wyeth Pharmaceuticals, added, “We are proud to be able to offer this new innovation to physicians and health care providers caring for palliative care patients with advanced illness. We are pleased to have received regulatory approvals for Relistor from Canada, the U.S., and Europe in quick succession, as they represent significantly developed markets for opioid use in palliative care patients.”

Commercial launch of Relistor in Europe will be rolled out on a country-by-country basis, with the first launch anticipated to occur later this month.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters